In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Mechanisms of endothelial cell activation by endocannabinoid 2-arachidonoylglycerol

Session Basic Science Vascular ePosters

Speaker Julian Jehle

Event : ESC Congress 2020

  • Topic : basic science
  • Sub-topic : Vascular Biology and Physiology
  • Session type : ePosters

Authors : J Jehle (Bonn,DE), L Eich (Bonn,DE), E Avraamidou (Bonn,DE), V Tiyerili (Bonn,DE), L Bindila (Mainz,DE), B Lutz (Mainz,DE), G Nickenig (Bonn,DE)

J Jehle1 , L Eich1 , E Avraamidou1 , V Tiyerili1 , L Bindila2 , B Lutz2 , G Nickenig1 , 1Heartcenter Bonn, University Hospital Bonn - Bonn - Germany , 2Johannes Gutenberg University Mainz (JGU) - Mainz - Germany ,

Basic Science - Vascular Biology and Physiology

Background: Endothelial dysfunction promotes atherogenesis, vascular inflammation, and thrombus formation. Reendothelialization after angioplasty is required in order to restore vascular function and to prevent stent thrombosis. The endocannabinoid (eCB) 2-arachidonoylglycerol (2-AG) is a known modulator of inflammation. Earlier studies have demonstrated the relevance of this endocannabinoid in human pathophysiology during coronary artery disease and in murine experimental atherogenesis. However, evidence on the impact of 2-AG on endothelial cell function remains scarce.

Methods: Endothelial repair was studied in two treatment groups of wildtype mice following electrical denudation of the common carotid artery. One group received the monoacylglycerol lipase (MAGL)-inhibitor JZL184, which impairs 2-AG degradation and thus causes elevated 2-AG levels, the other group received DMSO. The residual endothelial gap at five days was visualized by Evan’s blue staining in either group. In vitro, the effect of 2-AG on human coronary artery endothelial cell (HCAEC) viability was assessed by an XTT-based assay. Endothelial activation was studied by an adhesion assay of THP-1 monocytes to 2-AG-preconditioned HCAEC. Activation of HCAEC adhesion molecules was characterized by flow cytometry.

Results: Elevated 2-AG levels significantly impaired reendothelialization in wildtype mice following electrical injury of the common carotid artery, resulting in a residual denudation at 5 days of 2291 ± 286 µm vs. 1505 ± 223 µm (n = 18-19; p < 0.05). In vitro, 2-AG significantly reduced viability of HCAEC at 24 hours (0.31 ± 0.10 vs. 1.00 ± 0.08; n = 3; p < 0.01). Finally, 2-AG promoted HCAEC activation resulting in a significant increase in THP-1 monocyte adhesion to HCAEC following pre-treatment of HCAEC with 2-AG (0.17 ± 0.03 THP-1 cells per HCAEC vs. 0.07 ± 0.01 THP-1 cells per HCAEC; n = 3; p < 0.05). Adhesion molecules E-selectin, ICAM-1 and VCAM-1, that are known to be regulated by 2-AG in the venous endothelium, remained unchanged in arterial endothelial cells. Besides, HCAEC migration, ROS-production, expression of NADPH oxidases and secretion of inflammatory cytokines were unaffected by 2-AG.

Conclusion: Elevated 2-AG levels hamper endothelial repair and impair HCAEC proliferation while facilitating adhesion of monocytes. Intriguingly, the underlying mechanisms in the arterial vascular bed appear distinct from venous endothelium. Given that 2-AG is elevated during coronary artery disease in humans, 2-AG might impair reendothelialization after angioplasty and thus impact on clinical outcomes.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are